December #184 : The POZ 100-The Hunters

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Features

The POZ 100-Accelerating the End of AIDS

The POZ 100-The Seekers

The POZ 100-The Hunters

The POZ 100-The Defenders

The POZ 100-The Soldiers

The POZ 100-Cure All Glossary

Love is the Cure

From the Editor

More Than a Feeling

Feedback

Letters-December 2012

The POZ Q+A

Towards an HIV Cure

POZ Planet

A Very Big Kiki

Russians Deploy 'Google Bombs'

Home Alone

Say What-Paris Hilton

Back to School

What's a Buyers' Club? Matthew Knows.

iPad Video Game to Teach HIV Prevention Skills

Voices

Tried and True

Care and Treatment

One a Day to Keep Heart Attacks Away?

One Form to Rule Them All

Stribild is Here

T-Totaller

Nature's Little Helpers

GMHC Treatment Issues December 2012

Research Notes

Prevention: Selzentry Is PrEP Contender

Treatment: Dolutegravir Shows Promise

Cure: Curious Cohort on Early Treatment

Concerns: Fewer Comebacks From Heart Attacks

POZ Survey Says

Healthy Technology

POZ Heroes

Breaking Bad Cycles

   
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

December 2012

The POZ 100-The Hunters

POZ 100 Hunters
Click here to read a digital edition of this article.

Most likely it won’t be a single person—or a single research team or institution—to discover the cure for HIV. Just like it was with AIDS treatment research, it will be a massive endeavor requiring monumental collaborative work between test tube and animal scientists, the biotech and pharmaceutical industries, government and nongovernmental organizations, clinical trial experts and, of course, study volunteers.

In addition to the Seekers on the previous pages, the 27 researchers below further exemplify the scientific leadership chipping away at the mystery of HIV persistence, many of whom are also testing novel ways to achieve either eradication or functional cures in the greatest number of people with HIV.

Much of their work wouldn’t be possible without significant funding from sources such as the Martin Delaney Collaboratory at the National Institutes of Health; amfAR, The Foundation for AIDS Research; and the California Institute for Regenerative Medicine.  

Joseph Alvarnas and Richard Ambinder  
The City of Hope National Medical Center and Johns Hopkins University researchers are enrolling HIV-positive cancer patients into a transplant study that will involve donors with the CCR5-Delta32 mutation that confers resistance to HIV. They’re looking to duplicate the results of Timothy Brown’s case.

David Baltimore  
A 1975 Nobel Prize recipient currently at the California Institute of Technology, Baltimore is exploring why existing ARVs don’t clear HIV reservoirs—a step in figuring out what will work.

Paul Cameron  
The Melbourne-based Monash University scientist is focusing on tissue-based dendritic cells, which can become infected with HIV but don’t produce new virus. Figuring out what sets these cells apart from others can potentially be applied to curative approaches.

Paula Cannon  
Using zinc finger nucleases (ZFNs) to genetically alter CD4 cells is proving safe and effective in treatment studies. Laboratory work conducted by Cannon of the University of Southern California suggests it might be possible to do the same thing with stem cells to rebuild entire immune systems resistant to HIV, thus curing the virus. There are no studies in humans yet.

Julian Elliott  
Working with “Seeker” Steven Deeks, Monash University’s Elliott is testing the alcohol dependency drug Antabuse (disulfiram) as a way to flush HIV from its reservoirs. Like vorinostat (see “Seeker” David Margolis), disulfiram inhibits HDAC, a class of enzymes that keep HIV locked inside cells.

Koh Fujinaga  
While some researchers find ways to tease out HIV from its hiding spots in reservoirs, Fujinaga of the University of California at San Francisco has set out to understand what, exactly, happens inside cells that end up sequestering HIV in the first place.

Hiroyu Hatano  
Might a common blood pressure medication—an ACE inhibitor—successfully reduce fibrous tissue in lymph nodes, thereby allowing a more effective immune response against HIV, particularly in its hiding places? Hatano and her colleagues at the University of California at San Francisco are currently exploring this theory.

Frederick Hecht and Daniel Douek  
Hecht of the University of California at San Francisco is working with Douek of the NIH (along with “Seeker” Sarah Palmer) to test their theory that ARV-unaffected immune system cells can make copies of themselves and the virus they contain, thus creating HIV reservoirs. Figuring out which cells are involved, and how, will allow researchers to design ways to clear the reservoirs and cure HIV.

Timothy Henrich  
Was Timothy Brown cured of his HIV because of the chemotherapy, anti-CD4 cell antibody infusions, high-dose radiation or the HIV-resistant stem cells he received? It could have been one therapy or a combination of approaches. In working to figure out the answer, Henrich of Brigham and Women’s Hospital in Boston is helping drive new research. He also is investigating two more possible cure cases following bone marrow transplants.

Keith Jerome and Hans-Peter Kiem
Both of the Fred Hutchinson Cancer Research Center in Seattle, Jerome and Kiem are developing proteins known as endonucleases to target HIV. They’re also collaborating with Sangamo BioSciences to further study the use of gene therapies to render the immune system resistant to the virus.

Mathias Lichterfeld  
The Massachusetts General Hospital researcher will explore whether a newly discovered group of CD4 cells, dubbed T-memory stem cells, are a main site of HIV reservoirs that re-emerge after ARV therapy is stopped. His group will look at drugs to purge virus from these cells.

Robert Murphy  
The Northwestern University researcher heads the ERAMUNE-2 study (see the sister clinical trial by “Seeker” Christine Katlama), which intensifies HIV treatment to target actively replicating cells and then uses an Ad5 HIV vaccine, an immune-based therapy, to simultaneously attack the viral reservoirs. Preliminary results from both studies are expected soon.

Douglas Nixon  
Did you know that several ancient viruses, called HERVs, are embedded in our DNA and can become reactivated? By exploring the antibodies our immune systems produce to control these viruses, Nixon of the University of California at San Francisco is hoping to develop a vaccine that can produce antibodies against another DNA passenger: HIV.

Deborah Persaud
and Katherine Luzuriaga  
The Johns Hopkins and University of Massachusetts researchers, respectively, have been studying a handful of adolescents who contracted HIV at birth yet have no detectable virus and are antibody negative after spending their childhoods on ARVs. How do their viral reservoirs and immune systems differ compared with people who became HIV positive as adults? They’re looking to find out.

Lawrence Petz  
He’s the chief medical officer of StemCyte, a company collecting cord blood—samples collected from placentas and umbilical cords after birth—from donors with the favorable CCR5-Delta32 mutation. A catalog of usable cord blood cells should help transplant researchers looking to duplicate Timothy Brown’s results.

Quentin Sattentau  
“Big eater” (macrophage) cells can engulf cells containing HIV and potentially pass the virus along to other susceptible cells. Little is known about why this happens or what can be done about it; Sattentau of the University of Oxford hopes to learn more.

Rafick-Pierre Sekaly
and Mike McCune  
Sekaly of the Vaccine & Gene Therapy Institute of Florida and McCune of the University of California at San Francisco—in collaboration with “Seeker” Steven Deeks—have embarked on a seven-project initiative to define the nature and location of HIV reservoirs. Specifically, researchers hope to better understand how they’re created and maintained, and to test ways to eliminate them without broadly activating the immune system.

Robert Siliciano  
The Johns Hopkins University scientist has irons in many cure research fires. His lab has tested Timothy Brown’s blood samples, as well as a variety of drugs with the potential to purge HIV reservoirs. And by looking at HIV-infected CD4s exposed to HDAC inhibitors, the lab hopes to determine why some cells appear reluctant to release their viral payload.

John Tilton  
Some CD4 cells abort HIV infection; others go on to produce new virus immediately; and yet others end up locking the virus away. Tilton of Case Western Reserve University is focusing on these CD4 cell “subsets” to understand how HIV reservoirs are established and maintained.

Linos Vanderkerckhove  
Curative treatments are only as good as the tools available to detect low (or no) virus in samples. Vanderkerckhove of Ghent University Hospital in Belgium is developing a new test to measure the size of the reservoir and what happens to it in the presence and absence of HIV treatment.  

Bruce Walker   
Many scientists are focusing on ways to purge the virus from otherwise unreachable cells—the so-called HIV reservoirs. Walker and his colleagues of the Harvard Center for AIDS Research are instead focusing on the mechanisms of immune control that help some people keep the virus tucked away without the need for ARVs. His work with long-term nonprogressors and elite controllers is considered to be an integral component of functional cure research.

John Young  
Sulfonation is a type of chemical modification that needs to occur inside cells so that the virus can reproduce. Young, of the Salk Institute, thinks it may be possible to manipulate this, using safe and effective drugs, to help purge the virus from inactive cells in the body.



Introduction | The Seekers | The Hunters | The Defenders | The Soldiers | Cure-All Glossary |


To read the 2011 POZ 100, click here.
To read the 2010 POZ 100, click here.

Search: Martin Delaney Collaboratory, National Institutes of Health, amfAR, the Foundation for AIDS Research, California Institute for Regenerative Medicine

Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


         

[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dambitious
    Gone
    New York


    oceanblue65
    louisiana
    Louisiana


    OahuAJ
    Glendora
    California


    Fergie911
    Chicago
    Illinois
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Is HIV/AIDS adequately portrayed in pop culture?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.